BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 36384246)

  • 1. Prevention and management of secondary central nervous system lymphoma.
    Bobillo S; Khwaja J; Ferreri AJM; Cwynarski K
    Haematologica; 2023 Mar; 108(3):673-689. PubMed ID: 36384246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
    Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.
    Orellana-Noia V; Abousaud A
    Curr Treat Options Oncol; 2022 Oct; 23(10):1443-1456. PubMed ID: 36127571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS prophylaxis in aggressive B-cell lymphoma.
    Wilson MR; Bobillo S; Cwynarski K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):138-145. PubMed ID: 36485105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
    Roschewski M; Hodson DJ
    Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
    Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
    Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Habringer S; Demel UM; Fietz AK; Lammer F; Schroers R; Hofer S; Bairey O; Braess J; Meier-Stiegen AS; Stuhlmann R; Schmidt-Hieber M; Hoffmann J; Zinngrebe B; Kaiser U; Reimer P; Möhle R; Fix P; Höffkes HG; Langenkamp U; Büschenfelde CMZ; Hopfer O; Stoltefuß A; La Rosée P; Blasberg H; Jordan K; Kaun S; Meurer A; Unteroberdörster M; von Brünneck AC; Capper D; Heppner FL; Chapuy B; Janz M; Schwartz S; Konietschke F; Vajkoczy P; Korfel A; Keller U
    Eur J Cancer; 2024 Jan; 196():113436. PubMed ID: 38008033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.
    Simard J; Roschewski M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):709-717. PubMed ID: 35787364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
    Puckrin R; Chua N; Shafey M; Stewart DA
    Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I treat secondary CNS involvement by aggressive lymphomas.
    Alderuccio JP; Nayak L; Cwynarski K
    Blood; 2023 Nov; 142(21):1771-1783. PubMed ID: 37702537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
    El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
    Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
    Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
    Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
    Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
    Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
    Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas.
    Sahin U; Gokmen A; Soydan E; Urlu SM; Merter M; Gokgoz Z; Arslan O; Ozcan M
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e1-e13. PubMed ID: 36344419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.
    Santambrogio E; Nicolosi M; Vassallo F; Castellino A; Novo M; Chiappella A; Vitolo U
    Expert Rev Hematol; 2019 Sep; 12(9):787-796. PubMed ID: 31305170
    [No Abstract]   [Full Text] [Related]  

  • 18. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
    Puckrin R; El Darsa H; Ghosh S; Peters A; Owen C; Stewart D
    Am J Hematol; 2021 Jul; 96(7):764-771. PubMed ID: 33811794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
    Bobillo S; Wilson MR; Cwynarski K
    Curr Opin Oncol; 2023 Sep; 35(5):382-388. PubMed ID: 37551947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
    Lee MY; Kim HS; Lee JY; Lim SH; Kang ES; Ko YH; Kim SJ; Kim WS
    Int J Hematol; 2015 Dec; 102(6):678-88. PubMed ID: 26493833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.